Vivlion licenses CRISPR tech from ERS Genomics

By The Science Advisory Board staff writers

December 1, 2020 -- Vivlion has signed a nonexclusive license agreement to access ERS Genomics' CRISPR/Cas9 patent portfolio to enhance Vivlion's gene editing reagents and screening services.

Vivlioin, a German startup focused on next-generation CRISPR/Cas guide RNA (gRNA) libraries and screening services, holds an exclusive license to Goethe University of Frankfurt's proprietary 3Cs technology for the production of next-generation 3Cs CRISPR/Cas gRNA libraries.

The technology enables single and dual-combinatorial CRISPR/Cas libraries to be produced without compromising quality. This new license will enable Vivlion to offer both research and development reagents and screening services to its customers worldwide.

Financial details of the agreement were not disclosed.

If you like this content, please share it with a colleague!

Related Reading

ERS Genomics licenses gene editing tech to FASMAC
ERS Genomics, which has access to foundational CRISPR/Cas9 intellectual property co-owned by Emmanuelle Charpentier, has signed an agreement with FASMAC...

ERS Genomics inks licensing agreement with Applied StemCell
ERS Genomics said that it has signed a licensing agreement with Applied StemCell to commercialize CRISPR gene editing services and reagents.

Opposition fails for key CRISPR patent in Europe
ERS Genomics announced on February 10 that the European Patent Office has upheld an important CRISPR patent, rejecting opposition filed by anonymous parties.

ERS Genomics licenses CRISPR tech to Aelian
ERS Genomics announced on February 11 that it has entered an agreement to license its portfolio of CRISPR technology to Aelian Biotechnology.